acne vulgaris

New Data Highlights the Role of Olumacostat Glasaretil in Sebum Inhibition

Dermira biopharmaceuticals

A study published in the July 2017 issue Journal of Investigate Dermatology is shedding light on the mechanism of action of a new topical developed to treat acne vulgaris. Olumacostat glasaretil (formerly DRM01) from biopharmaceutical company Dermira was designed to inhibit acetyl coenzyme-A carboxylase (ACC), an enzyme that plays an important role in the synthesis of the lipids that make up sebum.

Sebacia Completes Enrollment in Pivotal U.S. Clinical Trial for Severe Acne

Sebacia has announced completion of enrollment in the U.S. randomized pivotal clinical trial investigating the use of the Sebacia Acne Treatment System, an investigational device that combines gold microparticles and laser energy to target acne. The gold microparticles are designed to be used with existing dermatologic lasers to heat the sebaceous glands and follicles.